VERAXA Biotech Begins Trading on NASDAQ, Advancing Diversified Oncology Pipeline

VERAXA Biotech AG (NASDAQ: VRXA) has been recognized as a company 'One to Watch' following its recent listing on the NASDAQ Capital Market. The biotechnology firm is advancing a diversified oncology pipeline that spans monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and proprietary BiTAC-based therapeutic formats across multiple cancer indications. This broad pipeline positions VERAXA within two rapidly growing segments of the global oncology therapeutics market: ADCs and T-cell engagers (TCEs).

The company's proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. This approach aims to address key challenges in cancer therapy by enhancing the precision of drug delivery and minimizing side effects. VERAXA's focus on ADCs and TCEs aligns with current industry trends, as these modalities offer significant potential for treating solid tumors.

VERAXA successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol 'VRXA' on June 11, 2026. This milestone provides the company with access to public capital markets to support its research and development efforts. Through selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs).

The company's vision is to deliver the next wave of smart cancer therapies with curative potential. VERAXA's pipeline includes multiple programs targeting various solid tumors, leveraging its expertise in antibody engineering. The BiTAC platform, in particular, represents a novel approach to conditional activation, which could differentiate VERAXA's therapies from conventional ADCs and TCEs.

Investors can find the latest news and updates relating to VRXA in the company's newsroom at https://ibn.fm/VRXA. VERAXA Biotech is headquartered in Switzerland and operates as a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors.

MissionIR, a specialized communications platform, highlighted VERAXA as a 'One to Watch' based on its promising pipeline and recent NASDAQ listing. MissionIR is part of the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, article syndication, and enhanced press release distribution. For more information about MissionIR, visit https://www.MissionIR.com.